Native and Engineered Extracellular Vesicles for the Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
Gu Z., Xue W., Mao G., Pei Z., Li J., Sun M.
Laboratory Study, published in Small Sci (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Small Sci (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40529885
- PMCID
- PMC12168619
- DOI
- 10.1002/smsc.202400606
Abstract (original English)
Extracellular vesicles (EVs) are lipid bilayer nanoparticles naturally released from cells, playing a crucial role in intercellular communication. They modulate gene expression and regulate physiological and pathological processes, including acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Research has shown that EVs contain a variety of active components, are biocompatible and small in size, and do not trigger immune rejection, making the infusion of exogenous EVs a promising therapeutic tool. With further research, engineering strategies have been proposed to enhance the clinical potential of EVs. These strategies involve modifying either donor cells that secrete EVs or the EVs themselves and can be engineered to circumvent the limitations of native EVs. In this review, an overview of the biological properties of native EVs is provided and the current therapeutic potential of native and engineered EVs in treating ALI/ARDS, along with the latest research findings, is summarized. The challenges and opportunities for clinical translation of EVs as a novel therapeutic tool are also discussed, offering new insights into the treatment of ALI/ARDS using EV engineering technology.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.